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Abstract
Background: Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome (TTP-
HUS) are related and uncommon disorders with a high fatality and complication rate if untreated.
Plasma exchange therapy has been shown to produce high response rates and improve survival in
patients with many forms of TTP-HUS. We performed a retrospective cohort study of 178
consecutively treated patients with TTP-HUS and analyzed whether clinical or laboratory
characteristics could predict for important short- and long-term outcome measures.
Results: Overall 30-day mortality was 16% (n = 27). 171 patients (96%) received plasma exchange
as the principal treatment, with a mean of 8 exchanges and a mean cumulative infused volume of
42 ± 71 L of fresh frozen plasma. The rate of complete response was 65% or 55% depending on
whether this was defined by a platelet count of 100,000/μl or 150,000/μl, respectively. The rate of
relapse was 18%. The Clinical Severity Score did not predict for 30-day mortality or relapse. The
time to complete response did not predict for relapse. Renal insufficiency at presentation was
associated with a decreased risk of relapse, with each unit increase in serum creatinine associated
with a 40% decreased odds of relapse. 72% of our cohort had an idiopathic TTP-sporadic HUS,
while 17% had an underlying cancer, received a solid organ transplant or were treated with a
mitomycin-based therapy. The estimated overall 5-year survival was 55% and was significantly
better in those without serious underlying conditions.
Conclusion: Plasma exchange therapy produced both high response and survival rates in this large
cohort of patients with TTP-HUS. The Clinical Severity Score did not predict for 30-day mortality
or relapse, contrary to our previous findings. Interestingly, the presence of renal insufficiency was
associated with a decreased risk of relapse. The most important predictor of mortality was the
presence or absence of a serious underlying disorder.
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Background
Thrombotic thrombocytopenic purpura and the hemo-
lytic uremic syndrome are rare, closely-related disorders
characterized by microangiopathic hemolytic anemia
(MAHA) and thrombocytopenia. Thrombotic thrombocy-
topenic purpura was first reported by Moschowitz in 1925
and is classically described as a pentad of hemolytic ane-
mia, thrombocytopenia, neurological symptoms, renal
involvement, and fever [1-3], although only a minority of
patients present with the complete pentad[4,5]. Hemo-
lytic uremic syndrome, first described by Gasser et al. in
1955[6], is often preceded by a diarrheal illness and
presents with MAHA and thrombocytopenia and a clinical
picture dominated by renal insufficiency. Significant
insights into the pathophysiology of these disorders have
recently been described. In the early 1980s, ultra large
multimers of von Willebrand factor (ULVWF) were found
in the plasma of thrombotic thrombocytopenic purpura
patients[7]. The presence of ULVWF was ultimately found
to be due to a lack of von Willebrand cleaving protease
activity, due either to congenital deficiency or an IgG
inhibitor [8-10]. This protease has been identified[11,12]
and designated ADAMTS13 (A disintegrin and metallo-
proteinase family with thrombospondin-like motifs) and
processes the ULVWF by proteolytic cleavage. Though
there are conflicting data, TTP is most often associated
with severe deficiencies of ADAMTS13 activity, whereas in
HUS activity of this protease is relatively preserved. Fur-
ther, pathologic differences have been observed between
malignancy and chemotherapy associated TTP-HUS as
compared to idiopathic/HIV-linked TTP and sporadic
HUS [13,14]; the former characterized by both micro and
macrovascular fibrin thrombi, as opposed to the microv-
ascular, platelet-rich angiopathy seen in the latter.
Without treatment, thrombotic thrombocytopenic pur-
pura is often a fatal disease, with a mortality rate in excess
of 95%[15]. Plasma exchange (PE) has been shown in sev-
eral case series to produce response rates of approximately
80% and survival rates greater than 90% [16-20]. The
effectiveness of plasma exchange was confirmed in a pro-
spective randomized clinical trial by the Canadian Apher-
esis Study Group, which demonstrated that PE was more
effective than simple plasma infusion in the treatment of
thrombotic thrombocytopenic purpura[19]. While the
role of plasma exchange in malignancy and chemother-
apy associated TTP is limited[1,14] the utility of PE in
patients with HUS is controversial, given common clinical
features and high morbidity of untreated TTP-HUS, with-
holding PE may be inappropriate[5,18,21]. Present prac-
tice at our institution and others[1] is to treat TTP and
HUS in a similar fashion.
We report a 24-year experience for 178 patients, predom-
inantly with idiopathic thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome (TTP-HUS), treated
principally with plasma exchange. This represents one of
the largest cohorts of TTP-HUS cases reported in the liter-
ature and provides insights into the clinical characteristics
at presentation, predictors of response and relapse, and
determinants of relapse and mortality.
Results
There were 178 patients included in this study, of whom
144 (81%) had TTP; the remainder had a diagnosis of
HUS. Table 1 presents characteristics of the cohort at the
time of diagnosis. About two-thirds of patients were
female, with an age range of 1.5 to 85 years. There were
fourteen patients 18 years or younger, and 7 patients 10
years or younger. Six patients 18 or younger had a diagno-
sis of HUS. These patients did not routinely undergo ther-
apeutic plasma exchange at our institution unless they
were refractory to supportive measures and at the discre-
tion of the treating pediatric hematologist. Of the 34
patients that carried the primary diagnosis of HUS, 6 were
18 years or younger.
Their ethnic distribution reflected the demographic char-
acteristics of our region, with about 32% non-Caucasian.
Twenty-eight percent of the patients had an underlying
serious medical disorder, as previously defined. The
median platelet count was 31,000/μL, with a range from
2,000 to 383,000/μL; the median hemoglobin level was
9.2 g/dL with a range of 1.7 to 16.0 g/dL. Initial platelet
and hemoglobin values were not available on some
Table 1: Patient Characteristics at the Time of Diagnosis
Number (Percent) or Mean ± SD
Age (years) 49 ± 20
Female 120 (68)
Ethnicity (n = 169)
White 114 (68)
Hispanic 21 (12)
African American 23 (14)
Asian 7 (4)
Other 4 (2)
Neurological symptoms 99 (59)
Fever 73 (44)
Hemoglobin (g/dl) 9.0 ± 2.1
Platelet count (per μL) 49,000 ± 57,000
Serum lactate dehydrogenase
(times upper limit of normal)
6.3 ± 8.1
Serum creatinine (mg/dL) 3.2 ± 2.6
Comorbid conditions
Cancer 14 (8)
Solid organ transplantation 10 (6)
HIV infection 9 (5)
Mitomycin-based therapy 6 (3)
E. coli O157:H7 infection 4 (2)
Sepsis 4 (2)
Hepatitis C 3 (2)Journal of Hematology & Oncology 2008, 1:23 http://www.jhoonline.org/content/1/1/23
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patients who had been transferred to our institution,
many of whom had already begun therapy. Thus, baseline
values at our institution did not reflect the values at pres-
entation. The serum creatinine level was less than 1.5 mg/
dL in 33% of patients, between 1.5 and 2.5 mg/dL in 25%,
and greater than 2.5 mg/dL in 42%. The serum lactate
dehydrogenase level (LDH) was elevated above the upper
limit of normal in all but 10 (6%) of the 158 patients in
whom an LDH level was available at the time of diagnosis.
A Clinical Severity Score could be assigned to 168
patients. The mean score was 4.4 ± 1.4, with a median of
4 and a range of 1 to 8.
Plasma exchange was the principal treatment in 171
(97%) patients with the remaining 7 patients receiving
either fresh frozen plasma infusion only (n = 2) or only
Staphylococcal protein A absorption column therapy (n =
2); no treatment information was available for the
remaining 3. Of those patients receiving PE, 19 received
fewer than 4 plasma exchanges and charts were not avail-
able for 3. Thus, 152 patients were assessable for response
to PE. The median number of PE was 8 (range 1–262).
The mean cumulative volume of fresh frozen plasma
infused was 42 ± 71 L, with a median of 22 L. Corticoster-
oids were administered in 27% of the patients, anti-plate-
let agents (aspirin or dipyridamole) in 14%, vincristine in
12%, and dialysis in 20%. Protein absorption column
therapy, intravenous immunoglobulins, splenectomy,
and fresh frozen plasma infusion without exchange were
each used in less than 5% of patients. One patient had
been treated with ticlopidine.
Using a cut-off value for the platelet count of 100,000/μL
to define a complete response, 124 of 152 (82%) patients
responded, including 97 (64%) complete responders and
27 (18%) partial responders (50,000–100,000/μL). There
were 28 (18%) treatment failures. Using a platelet count
of 150,000/μL to define a complete response, there were
81 (53%) complete responders, 39 (26%) partial
responders, and 32 (21%) treatment failures.
Twenty-seven (16%) of the 167 patients for whom we
have death information died within the first thirty days
following diagnosis, including 1 patient who died of an
HIV-related infection, 1 who died of sepsis, and 1 who
died of intracranial hemorrhage. Of the 23 patients who
died of TTP or HUS, 8 (35%) did not receive at least 3
plasma exchanges (including one who refused treatment)
and 1 had an initial complete response. There were 26
deaths after day 30 for which there was information as to
cause. Of these, three were attributed to TTP at day 34, 10
months, and 152 months. One late death, at 132 months,
was possibly related to TTP. Most of the other late deaths
were attributed to cancer, lung, and cardiovascular dis-
ease. Of the 125 patients with adequate follow-up data, 23
(18%) relapsed following an initial response.
Table 2 presents the results of the univariate logistic
regressions for 30-day mortality and relapse. None of the
patient characteristics were significantly associated with
30-day mortality. Interestingly, an increased initial serum
creatinine was associated with a lower odds ratio for
relapse. Table 3 presents the results of the multivariate
models. Serum creatinine was no longer significantly
associated with relapse in the multivariate model. Second-
ary analyses also investigated the univariate association
between the number of exchanges needed to achieve a
response for both platelet cutoffs (100,000/μL and
150,000/μL) and relapse, restricted to those individuals
who had a complete response at the particular cutoff.
There was no association for the 100,000/μL cutoff (OR:
1.07; 95% CI: 0.98–1.18; p-value: 0.15). There was, how-
ever, an association for the 150,000/μL cutoff, with higher
numbers of exchanges needed to reach a complete
response associated with a higher risk of relapse (OR:
1.08; 95% CI: 1.003–1.16; p-value: 0.04).
Table 2: Univariate associations between patient characteristics and 30-day mortality and relapse*
Variable (unit) 30-Day Mortality OR (95% CI) p-value Relapse OR (95% CI) p-value
Clinical Severity Score 1.29 (0.94–1.79) 0.12 0.87
(0.58–1.31)
0.51
Fever at presentation 0.77 (0.33–1.85) 0.56 0.55
(0.19–1.57)
0.26
Age 1.014 (0.99–1.04) 0.2 0.99
(0.96–1.01)
0.3
Platelet count (per μL) 1.0 (0.99–1.01) 0.94 1.0
(0.98–1.01)
0.72
Hemoglobin (g/dL) 1.03 (0.85–1.25) 0.77 0.93
(0.75–1.16)
0.52
Serum creatinine (mg/dL) 1.10 (0.95–1.28) 0.21 0.61
(0.39–0.94)
0.03
* There were no associations between gender, ethnicity, neurologic symptoms or serum lactate dehydrogenase levels and either 30-day mortality 
or relapse.Journal of Hematology & Oncology 2008, 1:23 http://www.jhoonline.org/content/1/1/23
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Figure 1 presents the Kaplan-Meier curves for all individu-
als included in the death analyses as well as for those indi-
viduals (n = 134) without serious underlying disorders,
including cancer, organ transplant, HIV/AIDS, or sepsis.
The estimated survival probability at 5 years is 54% for all
subjects and 66% for those without serious underlying
conditions. The estimated survival probability at 10 years
is 48% for all subjects and 57% for those without co-mor-
bidities. There was a significant difference in the survival
patterns between those with co-morbidities and those
without co-morbidities (p < 0.001).
Table 3: Multivariate logistic regression models between patient characteristics and 30-day mortality and relapse
30-Day Mortality Relapse
Variable (unit) OR 95% CI p-value OR 95% CI p-value
Clinical severity score (1 unit) 1.46 0.84–2.54 0.18 1.32 0.64–2.7 0.46
Fever at presentation 0.69 0.24–2.00 0.50 0.28 0.07–1.15 0.08
Age (1 year) 1.007 0.98–1.04 0.64 0.97 0.93–1.01 0.09
Platelets (1/μL) 1.00 0.98–1.02 0.9 1.02 0.99–1.05 0.20
Hemoglobin (1 g/dL) 1.19 0.90–1.58 0.2 1.07 0.81–1.41 0.7
Serum creatinine (1 mg/dL) 1.00 0.80–1.25 0.98 0.53 0.27–1.05 0.07
Lactate dehydrogenase (times upper limit of normal) 1.00 0.95–1.06 0.91 1.02 0.90–1.16 0.72
Neurological symptoms at presentation 1.54 0.41–5.75 0.5 1.25 0.27–5.74 0.77
Female 1.93 0.64–5,.89 0.25 0.92 0.26–3.27 0.9
Kaplan-Meier curve for 5 years of follow-up Figure 1
Kaplan-Meier curve for 5 years of follow-up. Using either univariate association or multivariate logistic regression model 
there was no association between CSS and either 30 day mortality or relapse (OR 1.29, p = 0.12; OR 0.87, p = 0.51; OR 1.46, 
p = 0.18, OR 1.32, p = 0.46, respectivelly).Journal of Hematology & Oncology 2008, 1:23 http://www.jhoonline.org/content/1/1/23
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Discussion and conclusion
This retrospective study represents one of the largest single
center clinical experiences with TTP-HUS treated predom-
inantly with plasma exchange. This report affirms findings
of other investigators in smaller cohorts of patients. How-
ever, this larger analysis contradicts our previous findings
that Clinical Severity Score[22] was predictive of mortality
and suggests that a longer time to response is associated
with a higher risk of relapse. It also suggests that the most
important determinant of long-term survival is the pres-
ence or absence of a serious underlying medical condi-
tion.
The baseline characteristic of our patients is similar to
those reported by others[5,20](Table 1). There was a
female predominance (68%) and a median age of 49. The
ethnicity was reflective of the population of California.
After MAHA and thrombocytopenia, neurological symp-
toms were the next most common manifestation, consist-
ent with other series[5] and further illustrative that the
pentad is found only in a minority of the patients. The
mean presenting platelet count was higher than in most
series[5,20], perhaps reflecting an increased sensitivity to
the diagnosis in our region. In contrast to other recent
series[20], this present cohort had a lower proportion of
patients with serious underlying conditions, drug-related
TTP-HUS, pregnancy, or alternative diagnoses. This must
be taken into account when interpreting our response and
mortality rates.
The overall response rate of 80–83% is similar to the 77%
previously reported by our group in a smaller cohort of
patients[18], and others in the literature[5,16,19,20,23].
The observed 30-day mortality of 16% is higher than the
mortality rate of 10% previously reported by our
group[18], but compares favorably to the 21.3% mortality
reported by Shamseddine et al[24] In the plasma
exchange arm of the Canadian Apheresis Study Group
trial, the mortality rate for the plasma exchange group at
four weeks was approximately 20%[19]. The majority of
our patient cohort (128/178 or 72%) had idiopathic TTP.
In this sub-group, the mortality and response rates are
similar to the corresponding idiopathic TTP sub-group
reported by Vesely et. al. (20% and 83%, respec-
tively)[20].
Our previous analysis[18] had shown that the Clinical
Severity Score (CSS) was a potentially useful predictive
variable for 30-day mortality. However, the CSS for this
expanded patient cohort failed to demonstrate a correla-
tion with either mortality or relapse. These findings are in
agreement with those of Vesely et. al. who reported that
no clinical or laboratory variable at presentation was pre-
dictive or relapse or survival[20].
Although this study did not have adequate power to ana-
lyze an association between time to response and death
(due to the low number of deaths at 30 days), we were
able to examine the association between time to response
and relapse. Our data show that a higher number of PE to
reach a platelet count of 150,000/μL was associated with
a higher risk of relapse; however, the OR was 1.08 and this
barely reached statistical significance (p = 0.04). This may
reflect the time required to correct ADAMTS13 activity;
unfortunately, such data are not available for this cohort.
Contemporary studies should examine whether there is
any correlation between the time to normalization of
ADAMTS13 activity and risk of relapse. If confirmed by
others, this would suggest that patients requiring a higher
number of PE to reach a complete response might require
longer therapy to prevent relapse. However, this hypothe-
sis would need to be tested in a clinical trial. The inverse
correlation between serum creatinine and risk of relapse
may also reflect ADAMTS13 activity levels.
The overall 5-year survival of about 55% in this cohort
was lower than seen in our previous report and long-term
data by others[25]. Potential reasons for this include a
somewhat older median age than reported by some
groups and excess deaths from serious underlying comor-
bid conditions. However, our data also confirm the better
survival in patients treated with plasma exchange without
underlying comorbidities, as reported by others[20,26].
There are several important limitations that must be con-
sidered when interpreting the results of this study. This
was a retrospective study with all of the attendant limita-
tions of such a method. This analysis spans twenty-four
years and may be influenced by 1) contextual therapies
considered appropriate at various points in time, 2) varia-
bility in the health care professionals providing primary
treatment and the care in the different hospitals where
treatment was delivered, and 3) the different apheresis
machines used during the study period. The influence of
ancillary treatments on our study parameters was not ana-
lyzed because of the small numbers of patients receiving
these treatments and the non-standardized means of
determining when, why, and how these treatments were
administered. Follow-up and mortality data were unavail-
able for a sizable number of patients because of the
number and geographic separation of the serviced hospi-
tals, the high migration (relocation) rates in our region,
and the unavailability of some charts. Some of the follow-
up data were culled from physician and/or patient inter-
view and thus subject to recall bias. Despite this relatively
large cohort of patients, the sample size is small limiting
the power to detect small differences among subgroups.
Ideally, ADAMTS13 antigen and activity levels would have
also provided greater insight into this cohort of patients.
Unfortunately, saving plasma from our patients was notJournal of Hematology & Oncology 2008, 1:23 http://www.jhoonline.org/content/1/1/23
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routine, and the assays were not available. However, there
is yet mixed data regarding the diagnostic and predictive
utility of ADAMTS13 activity levels in patients presenting
with clinical TTP/HUS[8,10,21,26-29].
During the time period of this study TTP-HUS was, and
remains today, a clinical diagnosis[1]. Thus, the results of
this study are still pertinent to the care of such patients
today. A major determinant of long-term survival is the
presence of a serious underlying co-morbidity. These find-
ings also reaffirm that plasma exchange is associated with
a high response rate and that no clinical parameters at
diagnosis predict for response or survival. Therefore,
aggressive plasma exchange should be attempted in all
patients with otherwise unexplained MAHA and throm-
bocytopenia.
Methods
Study Population
The study population included consecutive patients with
a diagnosis of TTP-HUS referred to the therapeutic apher-
esis service of the Sacramento Medical Foundation Blood
Center (SMFBC) and the University of California Davis
Medical Center (UCDMC) from 1978 through 2002.
SMFBC (now called Bloodsource) is a not-for-profit com-
munity blood center that serves 41 hospitals in a 17-
county area of Northern California with an estimated 2.8
million catchment area. From 1984–1988, the UCDMC
had an independent therapeutic apheresis service. Prior to
1984, and after 1988, all patients requiring plasma
exchange were treated by the SMFBC. The vast majority of
patients referred for treatment were seen in the greater
Sacramento area at 13 participating hospitals which
include large and smaller community hospitals. During
this period of time, there were no other apheresis services
in the region besides SMFBC and UCDMC. Therefore, all
patients referred for apheresis for TTP/HUS should have
been treated by one of these two services. All patients in
this analysis were required to have microangiopathic
hemolytic anemia characterized by schistocytes on the
peripheral blood smear and thrombocytopenia (defined
as a platelet count < 150,000/μL), with no other identifi-
able cause for the anemia and thrombocytopenia (e.g.,
disseminated intravascular coagulation, hypertensive cri-
sis, or eclampsia). All patients had normal prothrombin
and activated partial thromboplastin times.
Prior to September 1993, plasma exchanges were per-
formed using the Fenwal CS-3000 Blood Cell Separator or
the Haemonetics model V50 machines. After September
1993, all exchanges were performed using the Cobe Spec-
tra.
Study design and outcome variables
We performed a retrospective cohort study. The primary
study outcome was death from TTP-HUS within 30 days
of diagnosis and initiation of therapy. The secondary out-
comes were overall survival in patients who were followed
after hospital discharge, relapse rates and response rates to
plasma exchange. We evaluated possible factors that
might predict 30-day mortality and relapse. Further, we
describe the clinical characteristics of, and ancillary treat-
ments received by, the patients included in this analysis.
Data collection
A retrospective therapeutic apheresis chart review was
conducted using standardized forms and an explicit
abstraction process. Data unavailable from the therapeu-
tic apheresis charts were obtained from the actual hospi-
tal/medical records, if possible. Quality assurance was
performed by reviewing a random sample of medical
records. Long term follow-up information after hospital
discharge was collected either through review of the
appropriate office charts, follow-up questionnaires sent to
the referring physician, physician or patient interview, or
a combination of the above. Determination of cause of
death was done through review of medical records and/or
death certificates.
We collected information on demographic characteristics
(age, gender, race, date of initial treatment, site of treat-
ment), initial clinical presentation (presence of fever or
neurologic abnormalities), laboratory values at the time
of initial presentation (hemoglobin, hematocrit, platelet
count, serum lactate dehydrogenase, and serum creati-
nine), number of plasma exchanges required to achieve a
complete response (see below), total number of plasma
exchange treatments, total volume of plasma infused,
concurrent conditions deemed significant (underlying
malignancy, solid organ transplants, mitomycin therapy,
post-partum state, HIV/AIDS, and E coli H:0157 infec-
tion), and concurrent ancillary treatments for TTP-HUS
(corticosteroids, anti-platelet agents, vincristine, Staphyl-
coccal protein A adsorption column, intravenous gamma
globulins, hemodialysis, peritoneal dialysis, and splenec-
tomy).
As a measure of disease severity, patients were assigned a
previously described Clinical Severity Score [22] based on
four clinical and laboratory parameters, if available, at the
time of presentation (Table 4). The Severity Score incor-
porates the neurological, renal, and hematological abnor-
malities and is the sum of all the parameters, with a range
of 0–8 points. We had previously found a correlation
between this score and 30-day mortality[18].Journal of Hematology & Oncology 2008, 1:23 http://www.jhoonline.org/content/1/1/23
Page 7 of 8
(page number not for citation purposes)
Treatment
Plasma exchange therapy in our patients was initiated
within twenty four hours of diagnosis at 1.5 times the pre-
dicted plasma volume for the initial procedure(s). All
patients undergoing plasma exchange were treated in a
relatively uniform fashion, with daily exchanges until sta-
bilization of the platelet count above 100,000/μL associ-
ated with no new or progressive neurological deficits and
a declining serum lactate dehydrogenase level. When a
response was achieved, a slow plasma exchange taper was
initiated, usually involving every other day, three times
weekly, or twice weekly schedules before cessation of
treatment. This was at the discretion of the treating physi-
cian.
Response and relapse criteria
A complete response to plasma exchange was defined as a
platelet count greater than 100,000/μL for two consecu-
tive evaluations, declining lactate dehydrogenase levels (if
initially elevated), and no further neurological deficits or
progression. A partial response was defined as stabiliza-
tion of the platelet count below 100,000/μL with no fur-
ther neurological deficits or progression. To allow
comparisons with previous reports using 150,000 as the
response cutoff, we analyzed our data using this level as
well. Patients who had progressive thrombocytopenia,
worsening neurological deficits, or clinical deterioration
while undergoing plasma exchange therapy were deemed
treatment failures. Relapse (after a documented response)
was defined as the recurrence of any or all of the follow-
ing: the initial signs and symptoms, MAHA (associated
with an increase of LDH to > 500 U/L), thrombocytopenia
(< 100,000/μL), and abrupt or slowly progressive deterio-
ration in neurological status following cessation of
plasma exchanges. Responding patients who failed to fol-
low-up after the initial hospitalization for TTP-HUS were
censored from relapse determination. Neurologic impair-
ment included headaches, mental status changes (includ-
ing confusion, obtundation, and coma), acute sensory or
motor deficits, and seizures.
Statistical analyses
Primary outcomes for this study included 30-day mortal-
ity and relapse, with specific interest in the associations
between patient characteristics at the time of diagnosis of
TTP or HUS and these outcomes. Logistic regression was
the main model used to assess these associations. We
began by investigating the univariate associations, fol-
lowed by a multivariate model that included all patient
characteristics variables. Odds ratios (OR) and 95% confi-
dence intervals (CI) are reported. In addition, Kaplan-
Meier curves were used to investigate long-term survival
for patients with and without serious underlying disorders
(i.e., cancer, solid organ transplantation, HIV infection,
sepsis, hepatitis C, and E. coli O157:H7 infection), and a
log-rank test was used to test for differences in the survival
patterns. All analyses were performed using SAS, with a p-
value < 0.05 considered statistically significant. Continu-
ous data are reported as means ± SD, unless otherwise
noted.
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